FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036706037> ?p ?o ?g. }

• W3036706037 endingPage "757" @default.
• W3036706037 startingPage "749" @default.
• W3036706037 abstract "Previous studies have shown that DBDx, a combination consisting of dipyridamole, bestatin and dexamethasone is highly effective against several cancer xenografts in athymic mice. Here the therapeutic effects of DBDx and its combination with gemcitabine or capcitabine against human pancreatic cancer xenografts and the mechanism were studied. In vivo experiments performed in athymic mice showed that the antitumor efficacy of DBDx was much stronger than that of gemcitabine or capecitabine alone. Notably, the combination of DBDx and gemcitabine or capcitabine further enhanced the efficacy. In the case of DBDx (242 mg/kg) plus gemcitabine (100 mg/kg), tumor weight decreased about 97.7%, and tumor sizes were shrinking during the treatment. In the case of DBDx (242 mg/kg) plus capecitabine (718.7 mg/kg), tumor weight decreased about 94.9%. Moreover, DBDx and its combinations obviously prolonged theoverall survival of mice compared with gemcitabine or capcitabine alone. DBDx-based drug combination therapy showed no obvious systematic toxicity. The gene expression profile analysis showed that the genes changed by DBDx were related to immune system and tumor vasculature. The result of protein array showed that the changed proteins in the serum of treated mice were related to immune and inflammation system. These results show that DBDx-based drug combinations, a new strategy which integrates the use of low-cytotoxic drugs and cytotoxic chemotherapeutics, are highly effective regimens against human pancreatic cancer in athymic mice at well tolerated doses. DBDx-based drug combination therapy might provide new options for the treatment of pancreatic cancer." @default.
• W3036706037 created "2020-06-25" @default.
• W3036706037 creator A5003039594 @default.
• W3036706037 creator A5014334354 @default.
• W3036706037 creator A5027500357 @default.
• W3036706037 creator A5038588938 @default.
• W3036706037 creator A5064842058 @default.
• W3036706037 date "2020-06-17" @default.
• W3036706037 modified "2023-09-26" @default.
• W3036706037 title "DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice" @default.
• W3036706037 cites W1931508686 @default.
• W3036706037 cites W1968310941 @default.
• W3036706037 cites W1992489519 @default.
• W3036706037 cites W1994316362 @default.
• W3036706037 cites W2011422070 @default.
• W3036706037 cites W2011449731 @default.
• W3036706037 cites W2015727630 @default.
• W3036706037 cites W2083452953 @default.
• W3036706037 cites W2089333807 @default.
• W3036706037 cites W2101465269 @default.
• W3036706037 cites W2102509488 @default.
• W3036706037 cites W2112744681 @default.
• W3036706037 cites W2123344367 @default.
• W3036706037 cites W2132244108 @default.
• W3036706037 cites W2151253787 @default.
• W3036706037 cites W2165480504 @default.
• W3036706037 cites W2256715738 @default.
• W3036706037 cites W2272984102 @default.
• W3036706037 cites W2375726982 @default.
• W3036706037 cites W2516400838 @default.
• W3036706037 cites W2554987853 @default.
• W3036706037 cites W2561586883 @default.
• W3036706037 cites W2565135178 @default.
• W3036706037 cites W2589694608 @default.
• W3036706037 cites W4254119762 @default.
• W3036706037 doi "https://doi.org/10.1080/15384047.2020.1776580" @default.
• W3036706037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7515518" @default.
• W3036706037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32644888" @default.
• W3036706037 hasPublicationYear "2020" @default.
• W3036706037 type Work @default.
• W3036706037 sameAs 3036706037 @default.
• W3036706037 citedByCount "1" @default.
• W3036706037 countsByYear W30367060372021 @default.
• W3036706037 crossrefType "journal-article" @default.
• W3036706037 hasAuthorship W3036706037A5003039594 @default.
• W3036706037 hasAuthorship W3036706037A5014334354 @default.
• W3036706037 hasAuthorship W3036706037A5027500357 @default.
• W3036706037 hasAuthorship W3036706037A5038588938 @default.
• W3036706037 hasAuthorship W3036706037A5064842058 @default.
• W3036706037 hasBestOaLocation W30367060371 @default.
• W3036706037 hasConcept C102652120 @default.
• W3036706037 hasConcept C121608353 @default.
• W3036706037 hasConcept C126322002 @default.
• W3036706037 hasConcept C150903083 @default.
• W3036706037 hasConcept C154317977 @default.
• W3036706037 hasConcept C202751555 @default.
• W3036706037 hasConcept C203014093 @default.
• W3036706037 hasConcept C207001950 @default.
• W3036706037 hasConcept C2776694085 @default.
• W3036706037 hasConcept C2776999253 @default.
• W3036706037 hasConcept C2777909004 @default.
• W3036706037 hasConcept C2780035454 @default.
• W3036706037 hasConcept C2780210213 @default.
• W3036706037 hasConcept C2780258809 @default.
• W3036706037 hasConcept C2780401358 @default.
• W3036706037 hasConcept C502942594 @default.
• W3036706037 hasConcept C526805850 @default.
• W3036706037 hasConcept C55493867 @default.
• W3036706037 hasConcept C71924100 @default.
• W3036706037 hasConcept C86803240 @default.
• W3036706037 hasConcept C8891405 @default.
• W3036706037 hasConcept C98274493 @default.
• W3036706037 hasConceptScore W3036706037C102652120 @default.
• W3036706037 hasConceptScore W3036706037C121608353 @default.
• W3036706037 hasConceptScore W3036706037C126322002 @default.
• W3036706037 hasConceptScore W3036706037C150903083 @default.
• W3036706037 hasConceptScore W3036706037C154317977 @default.
• W3036706037 hasConceptScore W3036706037C202751555 @default.
• W3036706037 hasConceptScore W3036706037C203014093 @default.
• W3036706037 hasConceptScore W3036706037C207001950 @default.
• W3036706037 hasConceptScore W3036706037C2776694085 @default.
• W3036706037 hasConceptScore W3036706037C2776999253 @default.
• W3036706037 hasConceptScore W3036706037C2777909004 @default.
• W3036706037 hasConceptScore W3036706037C2780035454 @default.
• W3036706037 hasConceptScore W3036706037C2780210213 @default.
• W3036706037 hasConceptScore W3036706037C2780258809 @default.
• W3036706037 hasConceptScore W3036706037C2780401358 @default.
• W3036706037 hasConceptScore W3036706037C502942594 @default.
• W3036706037 hasConceptScore W3036706037C526805850 @default.
• W3036706037 hasConceptScore W3036706037C55493867 @default.
• W3036706037 hasConceptScore W3036706037C71924100 @default.
• W3036706037 hasConceptScore W3036706037C86803240 @default.
• W3036706037 hasConceptScore W3036706037C8891405 @default.
• W3036706037 hasConceptScore W3036706037C98274493 @default.
• W3036706037 hasFunder F4320321001 @default.
• W3036706037 hasIssue "8" @default.
• W3036706037 hasLocation W30367060371 @default.
• W3036706037 hasLocation W30367060372 @default.

• next